Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07268131 | TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria(TITAN-HCC) | recruiting | N/A | 30 | Fudan UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | not yet recruiting | Phase 1 | 120 | Iksuda Therapeutics Ltd.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04194775 | A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma | active not recruiting | Phase 3 | 534 | CStone PharmaceuticalsINDUSTRY | 6 | Jul 30, 2026 | clinicaltrials |
| NCT04337177 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | active not recruiting | Phase 1 | 20 | Valent Technologies, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06622057 | D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer | recruiting | Phase 3 | 240 | InnoPharmax Inc.INDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT04712643 | A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma | active not recruiting | Phase 3 | 342 | Hoffmann-La RocheINDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT05621499 | HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | active not recruiting | N/A | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05771480 | Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)(TOURMALINE) | active not recruiting | Phase 3 | 142 | AstraZenecaINDUSTRY | 8 | Jul 29, 2026 | clinicaltrials |
| NCT07732504 | AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation(HCC-AI-RECLAIM) | not yet recruiting | N/A | 2,000 | Tongji HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | not yet recruiting | — | 2,000 | University of OklahomaOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07733115 | QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer | recruiting | Phase 2 | 38 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07734857 | Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma | not yet recruiting | — | 100 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT06506955 | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | active not recruiting | Phase 2 / Phase 3 | 15 | Taiho Oncology, Inc.INDUSTRY | 5 | Jul 28, 2026 | clinicaltrials |
| NCT06710223 | Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab | active not recruiting | Phase 1 | 16 | University of California, San DiegoOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | recruiting | Phase 4 | 40 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07479485 | MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) | recruiting | Phase 1 / Phase 2 | 160 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07729917 | Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study | not yet recruiting | Phase 2 | 240 | Zhejiang UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma(HIMALAYA) | active not recruiting | Phase 3 | 1,324 | AstraZenecaINDUSTRY | 17 | Jul 27, 2026 | clinicaltrials |
| NCT07724951 | The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study | not yet recruiting | — | 400 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729033 | A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy. | not yet recruiting | Phase 2 | 28 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729592 | Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT07729618 | AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma(HCC-AI-SELECT) | not yet recruiting | N/A | 1,800 | Tongji HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT06193733 | Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial | active not recruiting | Phase 2 | 74 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07582315 | A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) | recruiting | Phase 3 | 538 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07606599 | A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure | recruiting | Phase 3 | 398 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07723534 | Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers | not yet recruiting | Phase 2 | 32 | Midhun MallaOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07726446 | Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06796114 | Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab(PREDICT-HCC) | recruiting | N/A | 120 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02711553 | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | active not recruiting | Phase 2 | 309 | Eli Lilly and CompanyINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT04521686 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | active not recruiting | Phase 1 | 200 | Eli Lilly and CompanyINDUSTRY | 9 | Jul 22, 2026 | clinicaltrials |
| NCT05208762 | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | recruiting | Phase 1 | 714 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT06192797 | Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-013) | recruiting | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05492136 | Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?(LIVERaTION) | recruiting | N/A | 720 | Hospital del MarOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07690683 | Patients With Hepatocellular Carcinoma (HCC)(FORCE) | not yet recruiting | N/A | 52 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07716345 | Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer | not yet recruiting | — | 100 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT04545957 | Jump: MR Simulation For Radiation Therapy Master Protocol(JUMP) | recruiting | N/A | 86 | Brigham and Women's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05194293 | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | active not recruiting | Phase 2 | 4 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07713290 | A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma | active not recruiting | Phase 1 | 6 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) | not yet recruiting | Phase 1 / Phase 2 | 90 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 20, 2026 | clinicaltrials |
| NCT04792801 | PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC(TEP CARE) | active not recruiting | — | 108 | University Hospital, LilleOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05148572 | Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular Carcinoma(PROSECT) | active not recruiting | — | 101 | National Cancer Centre, SingaporeOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06796803 | Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) | recruiting | Phase 2 / Phase 3 | 398 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06990659 | Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)(CHOC) | recruiting | N/A | 206 | University Hospital, AngersOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07710885 | Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer(FOENIX-BTC) | recruiting | Phase 3 | 784 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 4 | Jul 17, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2026source: clinicaltrials